Side effects of treatment for sickle cell anemia are common and range from minor to severe and must always be taken into account when making treatment decisions. Patients may also experience the following side effects to various degrees: fatigue, shortness of breath, chest pain, leg pain that can be alleviated by rest, cough, dizziness, headaches, and other dizziness-related symptoms.
These numbers should be seen as the total number of people affected, not the whole population, because only adults are currently being tested for [sickle cell anemia](https://www.withpower.com/clinical-trials/sickle-cell-anemia). The number of people with sickle cell disease is more likely to be underestimated.
Sickle cell anemia is a blood disorder in which hemoglobin S, a less sturdy, sicklier variant, precipitates into red blood cells, damaging and damaging them. Typically, people of African heritage, especially in sub-Saharan Africa, are affected. Sickle cell does not go away by itself; it continues to grow until, for many, the effects of sickling become painful. But there is a common, effective treatment. It has eliminated thousands of deaths in Africa from blood clots at the valves of the heart and other serious complications.
Signs of anemia, sickle cell include shortness of breath, tingling or pain in one area of the body (hands) and numbness or tingling around the arms or legs. Symptoms such as short breath, chest pain and ankle swelling is due to a complication from sickle cell disease, not anemia itself. These signs usually improve after delivery.\n
[Sickle cell disease (SCD) is a genetic, hereditary condition that causes red blood cells to be abnormally shaped. Anemia is a condition in which the patient's red blood cells are no longer able to carry oxygen efficiently.
Based on current knowledge, it cannot be recommended to try to cure a person's sickle cell illness: many of the existing approaches are only supportive treatments. However, it is likely that with the development of better therapies and treatment approaches the ability to cure sickle cell will be increased over the coming years.
Clinical trial subjects in the first group had lower sickle cell hemoglobin levels and better socioeconomic and health conditions than control subjects, so it would be inappropriate to conclude that the drug trial produced an effect that would not otherwise have occurred even in individuals with sickle cell disease otherwise. A well-controlled trial of aspirin for the prevention of PDA is warranted.
The effectiveness of the treatment is in many ways dependent on the underlying cause of the disease and also can vary within the same disease depending on the individual. These effects mean that treatment effectiveness can be affected by the underlying diagnosis of the individual, which is why any treatment must be specifically tailored towards the disease of the individual.
Most adults with a mean Hgb level under 12.0 g/dL will obtain a satisfactory Hgb response to sickle cell treatment. Some adults with Hgb levels>16.0 g/dL will obtain a partial Hgb improvement following sickle cell treatment. To ensure a full return to normal Hgb levels, sickle cell patients with Hgb levels>18.0 g/dL will be required to be treated indefinitely. Sickle cell patients who achieve a Hgb level of>16.0 g/dL may require a prolonged duration of chronic sickle cell treatment to prevent severe morbidity with the potential to develop severe sequelae, particularly in patients with anemia.
Sickle cell disease is a hereditary genetic disorder. There were advancements in the medical field that contributed to a better understanding of the disease. Sickling has not only been discovered to be a cause of the disease but has also been shown to be more pronounced after surgery. It has also been discovered that there is a relation between sickling and the blood vessels in the kidneys which can also be a source of complications. In addition, erythrocyte deformability (which determines transfusion of a patient's blood) could be the target of future treatments.
For a small cohort studied, it appears that anemia and sickle cell affect self-reported quality of life in a manner that reflects not only functional impairment, but psychometric distress. Although intervention has an immediate clinical impact in this population, it is difficult to say if this was due to the improvement in hematological parameters or the reduction in psychometric distress.